← Product Code [JWY](/productcode/JWY) · K983746 # MICROSTREP PLUS PANEL (K983746) _Dade Microscan, Inc. · JWY · Dec 9, 1999 · Microbiology · SESE_ **Canonical URL:** https://fda-staging.innolitics.com/device/K983746 ## Device Facts - **Applicant:** Dade Microscan, Inc. - **Product Code:** [JWY](/productcode/JWY.md) - **Decision Date:** Dec 9, 1999 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.1640 - **Device Class:** Class 2 - **Review Panel:** Microbiology ## Indications for Use To determine bacterial antimicrobial agent susceptibility ## Device Story MicroScan MICroSTREP plus Panel is an in vitro diagnostic device used to determine antimicrobial susceptibility of aerobic non-enterococcal streptococci, including S. pneumoniae. The device consists of a test panel containing the antimicrobial agent Amoxicillin at concentrations of 0.008 - 16 mcg/mL. In a clinical laboratory setting, the panel is inoculated with a bacterial sample and incubated for 20-24 hours at 35°C +/- 1°C in a non-CO2 incubator. Results are determined by visual reading of the panel according to the package insert. The output provides the clinician with susceptibility data, which assists in selecting appropriate antibiotic therapy for patients with streptococcal infections. ## Clinical Evidence Performance evaluated via external study using fresh and stock efficacy isolates and stock challenge strains. The device demonstrated acceptable essential agreement, reproducibility, and precision when compared to the NCCLS frozen reference panel. Quality control testing yielded acceptable results. ## Technological Characteristics Microdilution panel containing antimicrobial agent (Amoxicillin). Manual visual reading method. Incubation requirements: 20-24 hours at 35°C +/- 1°C in non-CO2 environment. ## Regulatory Identification An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases. ## Predicate Devices - NCCLS Frozen Reference Panels ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ DEC - 9 1999 # Dade Behring DADE MICROSCAN INC. 1584 Enterprise Boulevard West Sacramento, CA 95691 Tel: +1 (916) 372-1900 ### 510(k) Summary Information: | Device Manufacturer: | Dade MicroScan Inc. | |----------------------|----------------------------------------------------------------------------| | Contact name: | Sharolyn Lentsch, Regulatory Affairs Manager | | Fax: | 916-374-3144 | | Date prepared: | October 22, 1998 | | Product Name: | Microdilution Minimum Inhibitory Concentration (MIC) Panels | | Trade Name: | MicroScan® MICroSTREP plus™ Panel - Amoxicillin | | Intended Use: | To determine bacterial antimicrobial agent susceptibility | | Indication for Use | For use with aerobic non-enterococcal streptococci including S. pneumoniae | | Predicate device: | NCCLS Frozen Reference Panels | #### 510(k) Summary: The proposed MicroScan® MICroSTREP plusTM Panel demonstrated substantially equivalent performance with streptococcal isolates when compared with an NCCLS frozen Reference Panel, as defined in the FDA DRAFT document "Review Criteria for Assessment of Antimicrobial Susceptibility Devices" (dated May 31, 1991). The Premarket Notification (510[k]) presents data in support of the new MICroSTREP plus™ Panel with various antimicrobial agents. The external evaluation was conducted with fresh and stock Efficacy isolates and stock Challenge strains. The MICroSTREP plus™ Panel demonstrated acceptable Essential Agreement performance when compared with the frozen Reference panel. Reproducibility testing demonstrated acceptable reproducibility and precision with each of the antimicrobial agents tested. Quality Control testing demonstrated acceptable results for each of the antimicrobial agents tested. {1}------------------------------------------------ Image /page/1/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features the department's name encircling a symbol. The symbol consists of three stylized human figures or shapes that are interconnected. The figures are arranged in a way that suggests movement or progress. DEC - 9 1999 Food and Drug Administration 2098 Gaither Road Rockville MD 20850 Mr. Trevor Wall Regulatory Affairs Manager Dade MicroScan, Inc. 1584 Enterprise Boulevard West Sacramento, California 95691 Re: K983746 Trade Name: MicroScan® MICroSTREP plus™ Panel (AMOXICILLIN) Regulatory Class: II Product Code: JWY Dated: October 1, 1999 Received: October 4, 1999 Dear Mr. Wall: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. {2}------------------------------------------------ Page 2 Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html" Sincerely yours, Steven Sutman Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ Page Ol # 510(k) Number (if known): 长 98 3746 Device Name: MICroSTRED plus To pares - AMOXIC illio Indications For Use: The MicroScan® MICroSTREP plus™ Panel is used to determine antimicrobial susceptibility of aerobic non-enterococcal streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20-24 hours at 35℃ +/- 1℃ in a non-CO2 incubator, and read visually according to the Package Insert. This particular submission is for the addition of the antimicrobial AMOXICILLIN at concentrations of 0.008 - 16 mcg/ML to the test panel The organisms which may be used for AMOXICILLIN susceptibility testing in this panel are; Streptococcus pneumoniae ## (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Woodei Deebois Division of Clifical Laboratory Devices 510(k) Number_198374 **Prescription Use** (Per 21 CFR 801.109) OR Over-The-Counter Use_ (Optional Format 1-2-96) · --- **Source:** [https://fda-staging.innolitics.com/device/K983746](https://fda-staging.innolitics.com/device/K983746) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com